ESR1 Biomarker Testing in mBC with Dr. Kaklamani
Dr. Kaklamani shares clinical implications for why testing for ESR1 mutations in metastatic breast cancer is important, and practical considerations for testing and interpreting results.
Date of Last Review: April 08, 2025
Document Number: VV-MED-168128
Please rate your satisfaction with the content on the following statements:
Very Dissatisfied
Dissatisfied
Neutral
Satisfied
Very Satisfied
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice
Please rate your satisfaction with the content on the following statements:
Credibility of information
Relevance of the information to my needs
Confidence to implement the learnings in my clinical practice